Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01339650 | Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | PHASE1 | COMPLETED | 93 | — | — | May 6, 2011 | Nov 30, 2017 | Jan 2, 2018 | 3 | Netherlands |
Blood samples for pharmacokinetics of ABT-767 will be collected at designated time points
| Arm | Type | Description |
|---|---|---|
| ABT-767 | EXPERIMENTAL | ABT-767 monotherapy |
| Name | Type | Description |
|---|---|---|
| ABT-767 | DRUG | ABT-767 once or twice daily for a 28 day cycle |
Inclusion Criteria: 1. Subject must be ≥ 18 years of age. 2. Subjects must have histological or cytological confirmation of locally advanced or metastatic solid tumor, and a documented Breast Cancer Gene 1 or 2 mutation, or high grade serous ovarian, fallopian tube, or primary peritoneal cancer. 3....